What is the main purpose of this 8-K filing?

The main purpose of this 8-K filing is to report Gilead Sciences' earnings for the second quarter ended June 30, 2004, and to provide investors with a press release detailing these results.

Why is Gilead providing non-GAAP financial measures?

Gilead is providing non-GAAP financial measures because management uses them to monitor and evaluate the company's ongoing results and trends. They believe these measures are useful for investors as well, particularly by excluding unusual and infrequent transactions.

What specific transaction is being excluded from the non-GAAP results?

The specific transaction being excluded is the gain realized from the sale of warrants to purchase common stock of Eyetech Pharmaceuticals, Inc. This event is characterized as unusual in nature, size, and infrequency.

What does the inclusion of the Eyetech warrant sale indicate?

The inclusion of the Eyetech warrant sale, and the subsequent decision to exclude its gain from non-GAAP reporting, indicates a strategic move by Gilead to highlight the performance of its core business operations by setting aside a significant, one-off financial event.

GILD 8-K SEC Disclosure

Summary

Gilead Sciences, Inc. (GILD) filed a Form 8-K on July 29, 2004, to report its earnings for the quarter ended June 30, 2004. The primary focus of this filing is the accompanying press release, which details the company's financial performance and highlights the impact of a significant non-recurring event. Investors should pay close attention to the earnings results presented, with an emphasis on the company's strategic decision to exclude a one-time gain from the sale of warrants in Eyetech Pharmaceuticals, Inc. from its non-GAAP financial measures.

Key Highlights

1Gilead Sciences announced its financial results for the second quarter ended June 30, 2004.
2The company issued a press release on July 29, 2004, detailing its earnings.
3A key event discussed is the sale of warrants to purchase common stock of Eyetech Pharmaceuticals, Inc.
4Gilead is presenting non-GAAP financial measures to provide insight into core business performance.
5The non-GAAP measures exclude a gain from the sale of Eyetech warrants, described as an unusual, large, and infrequent transaction.
6Management believes excluding this gain offers a clearer view of ongoing results and trends.
7The filing includes the press release as Exhibit 99.1.

GILEAD SCIENCES, INC. 8-K Report (Jul 29, 2004)

Summary

Key Highlights

Frequently Asked Questions